Keywords: Pfizer, Ergonex, Terguride, PAH

Pfizer adds to its PAH portfolio, acquiring global rights to Ergonex’ drug candidate terguride

Article | 13 May 2010

Print This

Pfizer says it has entered into an agreement to acquire terguride, which is in development as a potential treatment for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in